| Telmisartan, ramipril, or both in patients at high risk for vascular events PJ Yusuf S, Teo KK New England Journal of Medicine 358, 1547-59, 2008 | 5029* | 2008 |
| Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus S BM New England Journal of Medicine 369, 1317, 2013 | 4332 | 2013 |
| Empagliflozin in Heart Failure with a Preserved Ejection Fraction FG Anker Stefan D, Butler J N Engl J Med 385, 2021 | 3603* | 2021 |
| Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes JB Green, MA Bethel, PW Armstrong, JB Buse, SS Engel, J Garg, R Josse, ... New England Journal of Medicine 373 (3), 232-242, 2015 | 3247 | 2015 |
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation MS Sabatine NEW ENGLAND JOURNAL OF MEDICINE 352, 1179, 2005 | 2943 | 2005 |
| Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. HAF Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan ... N Engl J Med 377 (13), 1228-1239, 2017 | 2129* | 2017 |
| Bivalirudin for patients with acute coronary syndromes GW Stone, BT McLaurin, DA Cox, ME Bertrand, AM Lincoff, JW Moses, ... New England Journal of Medicine 355 (21), 2203-2216, 2006 | 1771 | 2006 |
| Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. FR Fox K, Ford I, Steg PG, Tendera M, B Investigators. Lancet 372, 807, 2008 | 1494 | 2008 |
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised … TK Yusuf S Lancet 372, 1174-83, 2008 | 1249 | 2008 |
| Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction A PW New England Journal of Medicine 382, 1883-1893, 2020 | 1186 | 2020 |
| Prasugrel versus clopidogrel for acute coronary syndromes without revascularization MT Roe New England Journal of Medicine, 2012 | 1108 | 2012 |
| Microcirculation in Hypertension A New Target for Treatment? BI Levy, G Ambrosio, AR Pries, HAJ Struijker-Boudier Circulation 104 (6), 735-740, 2001 | 984 | 2001 |
| Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term … O Chioncel, M Lainscak, PM Seferovic, SD Anker, MG Crespo‐Leiro, ... European journal of heart failure 19 (12), 1574-1585, 2017 | 975 | 2017 |
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes P Tricoci, Z Huang, C Held, DJ Moliterno, PW Armstrong, F Van de Werf, ... New England Journal of Medicine 366 (1), 20-33, 2012 | 918 | 2012 |
| Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. M Konstam Lancet 374, 1840, 2009 | 819 | 2009 |
| From endothelial dysfunction to atherosclerosis S Sitia, L Tomasoni, F Atzeni, G Ambrosio, C Cordiano, A Catapano, ... Autoimmunity reviews 9 (12), 830-834, 2010 | 773 | 2010 |
| Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. G Ambrosio, JL Zweier, C Duilio, P Kuppusamy, G Santoro, PP Elia, ... Journal of Biological Chemistry 268 (25), 18532-18541, 1993 | 661 | 1993 |
| Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. G Ambrosio, HF Weisman, JA Mannisi, LC Becker Circulation 80 (6), 1846-1861, 1989 | 632 | 1989 |
| Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Teerlink JR N Engl J Med 384, 105-116, 2021 | 593 | 2021 |
| Reperfusion injury: experimental evidence and clinical implications G Ambrosio, I Tritto American heart journal 138 (2), S69-S75, 1999 | 497 | 1999 |
David A. KassJohns Hopkins UniversityVerified email at jhmi.edu
